• Ginsenoside Rg6 and Cisplatin Resistance in Ovarian Cancer

  2026-08-30

  The reference study identifies a mechanistic link between aberrant fucosylation, the GRB2–ERK1/2–mTOR axis, autophagy, and cisplatin resistance in epithelial ovarian cancer cells. Its findings suggest that ginsenoside Rg6 may restore cisplatin sensitivity by promoting autophagy, reducing CTR1 core fucosylation, and increasing intracellular cisplatin uptake, although the evidence remains preclinical.

• AMG 487 CXCR3 Antagonist Workflow

  2026-08-29

  AMG 487 enables ligand-specific CXCR3 pathway dissection across calcium flux, chemotaxis, macrophage polarization, and autophagy assays. Its strongest use-case is state-aware experimentation, where inflammatory and non-inflammatory macrophages can respond differently to the same CXCL10–CXCR3 perturbation.

• Bovine Insulin for Metabolic Cell Culture Assays

  2026-08-28

  Bovine insulin supports reproducible cell expansion while providing a controllable variable for glucose metabolism regulation and pathway-focused assays. This guide translates melanoma metabolism findings into practical workflows for dosing, ROS and PDH readouts, assay controls, and troubleshooting.

• FUS–SMN Phase Separation in Neuronal Granules

  2026-08-28

  Wang and Li show that asymmetric arginine dimethylation enables FUS to engage the oligomeric Tudor-domain protein SMN, increasing multivalent interactions and promoting phase separation. The study connects this molecular mechanism to neuronal granule formation, axonal mRNA distribution, and defects associated with reduced SMN valency in spinal muscular atrophy.

• MK 0893: Glucagon Receptor Antagonist Mechanism

  2026-08-28

  MK 0893 is a competitive, reversible glucagon receptor antagonist that blocks human GCGR signaling through an extra-helical allosteric pocket. Nanomolar binding and cAMP inhibition make it a useful tool for type 2 diabetes research, while its receptor selectivity and formulation limits require controlled assay design.

• Acridine Orange hydrochloride: Practical Guide

  2026-08-27

  Acridine Orange hydrochloride provides membrane-permeable, differential fluorescence for examining nucleic-acid-associated signals in cells. It is suitable for fresh cytochemical workflows, cell cycle analysis, apoptosis detection, and flow-based DNA/RNA assessment, but it should not be treated as a sequence-specific probe or stored long-term as a solution.

• Methyl-β-cyclodextrin: Membrane Study Workflow

  2026-08-26

  Methyl-β-cyclodextrin (MβCD) is used to extract cholesterol and other hydrophobic lipids from biological membranes, enabling controlled studies of membrane organization, fluidity, and lipid-dependent signaling. It is intended for research workflows only, not diagnostic or medical use, and requires fresh solution handling and matched controls for reproducible interpretation.

• ATRX-Deficient Glioma and RTK Inhibitor Sensitivity

  2026-08-26

  Pladevall-Morera and colleagues identified a genotype-linked vulnerability in high-grade glioma: ATRX-deficient cells were more sensitive to several multi-targeted receptor tyrosine kinase and PDGFR inhibitors. The study further showed pronounced toxicity when RTK inhibition was combined with temozolomide, supporting ATRX-aware interpretation and stratification of future glioma treatment studies.

• TRPV1/TRPA1 Redox Sensing by 1O₂ and H₂O₂

  2026-08-26

  A 2026 Redox Biology study shows that TRPV1 and TRPA1 distinguish singlet oxygen from hydrogen peroxide rather than treating both as equivalent oxidative signals. By combining channel-function measurements, calcium imaging, agonist discrimination, and residue-focused analysis, the work identifies divergent channel responses with implications for designing redox-sensitive ion-channel experiments.

• PA-824: From Prodrug to Respiratory Assay Strategy

  2026-08-25

  PA-824 is a bicyclic nitroimidazole derivative whose activity against tuberculosis reflects both cell-wall disruption and respiratory stress. This article translates recent pretomanid findings into a state-aware assay strategy for studying Mycobacterium tuberculosis, persistence, synergy, and resistance.

• Gastric Cancer Assembloids for Patient-Specific Drug Testing

  2026-08-24

  Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine tumor organoids with matched stromal cell subpopulations from the same tumor. The model preserved clinically relevant tumor–stroma interactions and revealed that stromal composition can reshape gene expression and drug sensitivity, supporting more physiologically informed personalized screening.

• Coronavirus Macrodomains and PARP-Mediated Antiviral Defense

  2026-08-24

  The reference study identifies PARP12 and PARP14 as host factors that restrict coronavirus macrodomain-mutant replication while supporting interferon production. By combining pharmacological inhibition, targeted knockdown, cell-based infection models, and mouse experiments, it shows that the viral macrodomain counteracts PARP-dependent antiviral pressure rather than acting as an isolated viral enzyme.

• CP-673451: PDGFR Selectivity in Glioma Research

  2026-08-23

  CP-673451 is a selective PDGFRα/β inhibitor that connects precise target engagement with angiogenesis and glioma models. This article presents a genotype-aware framework for interpreting PDGFR assays, with special attention to ATRX-deficient high-grade glioma research.

• Fluo-4 AM: Calcium Imaging for Bioelectronic Insight

  2026-08-22

  Fluo-4 AM enables real-time intracellular calcium measurement with a practical workflow for cell signaling, pharmacology, and emerging retinal bioelectronics. This article translates artificial-photoreceptor findings into better calcium-assay design without confusing optical device output with cellular Ca2+ responses.

• Nintedanib in ATRX-Deficient Glioma Research

  2026-08-21

  Nintedanib (BIBF 1120) provides a practical way to interrogate coordinated VEGFR, FGFR, and PDGFR signaling in cancer and angiogenesis models. When paired with ATRX-stratified glioma systems, it can help test whether receptor tyrosine kinase dependence predicts response and whether combination treatment merits deeper study.

545 records 6/37 page Previous Next First page 上5页 678910 下5页 Last page